Health
Anti-phospholipid antibodies in severely ill patients not distinctive to COVID-19, says study – News-Medical.Net
A new study by researchers at the University of Toronto and the University of Calgary in Canada indicates that the presence of these antibodies correlates with…
Recent research indicates the occurrence of thromboembolic complications involving anti-phospholipid antibodies (APLA) and the anti-phospholipid syndrome (APS) in severe coronavirus disease 2019 (COVID-19). However, conflicting reports have emerged.
A new study by researchers at the University of Toronto and the University of Calgary in Canada indicates that the presence of these antibodies correlates with more severe COVID-19 symptoms and signs.
The team have released their findings as a preprint…
Continue Reading
